Early Intervention in Parkinson's Disease with Cabergoline – Results of an Open-Label Long-Term Trial with Focus on Sleep Disturbances

Aims: Cabergoline (CBG), a long-acting ergoline derivative, is frequently used for the add-on treatment of Parkinson's disease (PD). Study Objectives: To assess the safety and efficacy of CBG for the first-line treatment of PD with special regard to disease-/treatment-related sleep disturbances. Design: open-label, long-term (52 weeks), multicentre observational trial. Setting: 245 patients (44.9% female) with an age of 63.6±10.3yrs. and a diagnosis of early idiopathic PD (mean disease duration was 13.0±17.8 mos.). Intervention: CBG was uptitrated according to individual efficacy and tolerability effects. Measur…